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Abstract
Background: We demonstrated that a Chinese herbal formula, which we refer to as RCM-101,
developed from a traditional Chinese medicine formula, reduced nasal and non-nasal symptoms
of seasonal allergic rhinitis (SAR). The present study in primary and cultured cells was
undertaken to investigate the effects of RCM-101 on the production/release of inflammatory
mediators known to be involved in SAR.
Methods: Compound 48/80-induced histamine release was studied in rat peritoneal mast cells.
Production of leukotriene B4 induced by the calcium ionophore A23187 was studied in porcine
neutrophils using an HPLC assay and lipopolysaccharide-stimulated prostaglandin E2 production
was studied in murine macrophage (Raw 264.7) cells by immune-enzyme assay. Expression of
cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) was determined in Raw 264.7 cells,
using western blotting techniques.
Results: RCM-101 (1–100 μg/mL) produced concentration-dependent inhibition of compound
48/80-induced histamine release from rat peritoneal mast cells and of lipopolysaccharide-
stimulated prostaglandin E2 release from Raw 264.7 cells. Over the range 1 – 10 μg/mL, it
inhibited A23187-induced leukotriene B4 production in porcine neutrophils. In addition, RCM-
101 (100 μg/mL) inhibited the expression of COX-2 protein but did not affect that of COX-1.
Conclusion:  The findings indicate that RCM-101 inhibits the release and/or synthesis of
histamine, leukotriene B4 and prostaglandin E2 in cultured cells. These interactions of RCM-101
with multiple inflammatory mediators are likely to be related to its ability to reduce symptoms
of allergic rhinitis.
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Background
Allergic rhinitis, in particular seasonal allergic rhinitis
(SAR) or hay fever, is a common allergic condition [1].
World-wide, SAR afflicts 10 – 40% of individuals [2], with
approximately 20% affected in the United States, 13% in
Western Europe [3] and 16.1% in Australia [4]. SAR is an
immune response to a wide variety of pollens from
grasses, weeds and trees. It involves the interaction of
allergens with specific immunoglobulin E (IgE) antibod-
ies bound to high affinity Fcε receptors on the surface of
mast cells and basophils in the nasal mucosa [5]. This
interaction causes degranulation of these cells, releasing a
number of inflammatory mediators which are responsible
for a cascade of symptoms. Histamine, tryptase, prostag-
landin and bradykinin are responsible for the immediate
allergic response of sneezing, nasal itch and rhinorrhoea
[5]. The late phase response, usually 4 – 6 hours after the
immediate response, involves a large increase of eosi-
nophils, basophils and other leukocytes at the inflamma-
tory sites, in response to chemoattractants. In the late
phase response, it is likely that histamine and leukotrienes
are released from basophils rather than from mast cells
because there is no corresponding increase in tryptase
which originates from mast cells [5].
The conventional management of SAR is usually sympto-
matic, with histamine H1 receptor antagonists, sympatho-
mimetic amine vasoconstrictors and corticosteroids.
However, these treatments frequently have certain unde-
sirable side effects and, often do not provide complete
symptom relief [6]. Except corticosteroids, which have
more significant side-effects, conventional treatments
usually target a single inflammatory mediator, which
probably explains their limited effectiveness [7].
Complementary/alternative therapies are becoming
increasingly used in Western countries for the treatment
of allergic diseases, with growing perceptions that such
treatments are effective and that they are associated with
fewer and less severe side effects [8]. Certain Chinese
herbal formulae have been reported to be beneficial for
the treatment of asthma and allergic rhinitis, including
SAR, with some results showing that their effectiveness is
comparable to prednisolone [8]. Recently, we conducted
a randomized placebo-controlled clinical trial on a Chi-
nese herbal formula which was developed from a tradi-
tional Chinese medicine formula for the treatment of
symptoms associated with rhinitis. The formula was opti-
mized on the basis of Chinese medicine syndrome theory
for the treatment of SAR. We demonstrated that, after
eight weeks of treatment, the herbal medicine formula,
which we refer to as RCM-101, was effective in reducing
the nasal and non-nasal symptoms of SAR [9].
In a previous investigation of the possible mechanism(s)
of the anti-inflammatory/anti-allergic activity of RCM-
101 in SAR, we found that the herbal formula inhibited
histamine release from isolated guinea-pig tracheal prep-
arations and the production of nitric oxide and prostag-
landin E2 by cultured macrophages [10]. In the present
study, as an extended investigation into the pharmacolog-
ical activities of RCM-101 in reducing the symptoms of
SAR, we have investigated its effects on histamine release,
leukotriene B4 (LTB4) and prostaglandin E2 (PGE2) pro-
duction, and the expression of two enzymes involved in
inflammatory processes, namely cyclooxygenase-1 (COX-
1) and cyclooxygenase-2 (COX-2).
Methods
All experimental procedures involving animals were
approved by RMIT University Animal Ethics Committee
and were conducted in compliance with the Australian
National Health and Medical Research Council guide-
lines.
Histamine, LTB4 and PGE2 are three key inflammatory
mediators in allergic conditions such as SAR. To investi-
gate the effects of RCM-101 on the synthesis/release of
these mediators, we used three well characterized cell-
based models, namely rat peritoneal mast cells for hista-
mine [11], porcine neutrophils for LTB4 [12] and murine
macrophage cells (Raw 164.7) for PGE2 [13,14].
Preparation and extraction of RCM-101
RCM-101 is a herbal formula with 18 herbal ingredients,
modified from a traditional Chinese medicine formula.
Each herb for the formula was supplied in a granulated
form produced under Good Manufacturing Practices by
Min Tong Pharmaceutical Company (Taichong, Taiwan)
which holds certification from the Australian Therapeutic
Goods Administration (TGA-GMP No: 1888). Authenti-
cated, quality-certified raw herbs were first tested to
ensure that they were free of heavy metals. They were then
washed, dried and extracted in boiling water for 1 – 1.5
hour. The aqueous extract was separated by filtration (100
mesh) and the water content was reduced to 60% by heat-
ing (50 – 60°C) under reduced pressure (50 – 70 mmHg)
for 2 – 5 hours. The concentrated extract of each herb was
combined with starch as an excipient and the product was
dried and ground into fine granules. For each preparation,
1 g of granulated product was equivalent to 5 g of the raw
herb. The granulated herbal preparations were sterilised
and sealed in plastic bottles. In our laboratory, the granu-
lated preparations of the herbs were combined in the pro-
portions given in Table 1 to produce the herbal formula.
All herbal ingredients of RCM-101 are approved in the
Australian Register of Therapeutic Goods as active raw
herbs for use in medicines.Chinese Medicine 2007, 2:2 http://www.cmjournal.org/content/2/1/2
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The herbal formula was extracted with ethanol (120 mg/
mL) at room temperature with continuous agitation for 4
hours. The ethanol extract was collected by centrifugation
(5000 rpm for 10 minutes) and vacuum filtration. The
extract was dried using a rotary evaporator (Büchi
Rotavapor, Brinkman Company, Westbury, NY, USA) and
stored below -20°C. It was diluted to the required concen-
trations on the day of use.
Reagents
Compound 48/80, histamine hydrochloride, O-phthalal-
dehide, spermidine hydrochloride, bovine serum albu-
min (BSA), phosphate buffer saline, heparin, disodium
ethylenediaminetetraacetic acid (EDTA), lipopolysaccha-
ride (LPS) E.Coli, calcium ionophore A23187, Hanks' bal-
anced salt solution, RPMI 1640 medium, fetal bovine
serum, phenylmethylsulfonyl fluoride, gentamycin, leu-
peptin, pepstatin A and nordihydroguaiaretic acid
(NDGA) were obtained from Sigma Chemical Company
(St Louis, MO, USA). Monoclonal mouse anti-rat cycloox-
ygenase 2 antibodies and mouse macrophage lysate were
obtained from Transduction Laboratories (Lexington, KY,
USA). Goat anti-rabbit horseradish peroxidase conjugated
immunoglobulin G was obtained from Dako Corporation
(CA, USA). The Coomassie blue protein assay kit was pur-
chased from Bio-Rad (USA). Polyclonal rabbit anti-mouse
cyclooxygenase-1 antibody, immune-enzyme analysis
PGE2 kit, arachidonic acid, prostaglandin B2, LTB4, 6-trans
LTB4, 6 trans-12 epi LTB4, 5-hydroxyeicosatetraenoic acid
(5-HETE) and 15-hydroxyeicosatetraenoic acid (15-
HETE) were obtained from Cayman Chemical Company
(Ann Arbor, MI, USA). HPLC-grade methanol was sup-
plied by Selby-Biolab (Clayton, Victoria, Australia). All
other analytical reagents were obtained from Merck Pty
Ltd (Kilsyth, Victoria, Australia).
Histamine release from rat peritoneal mast cells
Rat peritoneal mast cells were collected in Tyrode buffer as
previously described [11]. Briefly, rats (Sprague-Dawley,
200 – 300 g) of either sex were killed and 10 mL of Tyrode
buffer (NaCl, 137 mM; KCl, 2.7 mM; HEPES, 10 mM;
MgCl2, 1 mM; CaCl2, 1.0 mM; NaH2PO4, 0.41 mM), con-
taining 0.3% BSA and 5 units/mL heparin was injected
into the peritoneal cavity. The abdomen was gently mas-
saged for about 90 seconds, and then carefully opened
and the cell-containing peritoneal fluid collected with a
transfer pipette. The cell-containing fluid was centrifuged
at 4°C at 800 rpm for 5 minutes. The cells were collected,
washed in 10 mL of Tyrode buffer and centrifuged again.
This procedure was repeated twice [11]. The cells were
then suspended in the concentration of 1 × 106 cells/mL
in 10 mM HEPES-Tyrode buffer (pH 7.4) containing 0.1%
BSA.
The 200 mL peritoneal cell suspensions were incubated
with various concentrations of RCM-101 for 10 minutes
at 37°C and then exposed to compound 48/80 for 10
minutes. Aliquots of 100 μL of rat peritoneal mast cells in
Tyrode buffer were combined with 100 μL aliquots of
RCM-101 extract in Tyrode buffer such that 5 × 105 cells/
mL were incubated with RCM-101 at concentrations of 1,
10 and 100 μg/mL for 10 minutes immediately prior to
stimulation of the cells with compound 48/80. The cell
suspensions were then centrifuged at 4°C at 4800 rpm
Table 1: Herbal constituents of RCM-101 (% of granulated herbs by weight*)
Scientific name Botanical name Chinese name %
Flos Magnoliae Magnolia liliflora (Desr.) Xin Yi 3.81
Frutus Schisandrae Chinensis Schisandra Chinensis (Turcz.) Wu Wei Zi 2.25
Frutus Terminaliae Chebulae Terminalia chebula Retz. He Zi 13.87
Frutus Xanthii Sibirici Xanthii Sibirici Patr. Ex Widd. Cang Er Zi 7.11
Herba Asari Asarum sieboldii Miq. Xi Xin 3.81
Herba Menthae Haplocalysis Mentha haplocalyx Briq. Bo He 4.68
Herba Schizonepetae Tenuifoliae Schizonepeta Tenuifolia Briq. Jing Jie 14.21
Pericappium Citri Reticulatae Citrus reticulata Blanco Chen Pi 9.36
Radix Angelicae Sinensis Angelica sinensis (Oliv.) Diels Dang Gui 4.68
Radix Astragali Membranaceus Astragalus membranaceus (Fisch.) Bge Huang Qi 4.68
Radix Bupleuri Bupleurum chinense D.C Chai Hu 3.81
Radix Codonopsitis pilosulae Codonopsis pilosula (Franch.) Nannf. Dang Shen 2.25
Radix Glycyrrhizae Uralensis Glycyrrhiza uralensis (Fisch.) Gan Cao 4.68
Radix Saposhnikoviae Divaricata Saposhnikovia divaricata (Turcz.) Fang Feng 4.51
Rhizoma Atractylodis Macrocephalae Atractylodes macrocephala Koidz Bai Zhu 4.68
Rhizoma Cimicifugae Cimicifuga foetida L. Sheng Ma 4.68
Rhizoma Ligustici Chuanxiong Ligusticum chuanxiong (Hort.) Chuan Xiong 4.68
Semen Plantaginis Plantago asiatica L. Wild. Che Qian Zi 2.25
* 1 g of each granulated herb is equivalent to 5 g of the raw herb (dry weight).Chinese Medicine 2007, 2:2 http://www.cmjournal.org/content/2/1/2
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and the supernatant collected. As an internal standard, 10
μL of spermidine (1 mg/mL) was added to 200 mL aliq-
uots of the supernatant, followed by 20 μL of 30% per-
chloric acid (HCIO4). The mixture was then filtered and
100  μL was transferred into HPLC vials for histamine
determination [11]. The Ca2+ chelating agent, EDTA, (100
μM) was used as a positive control.
The HPLC system (Shimadzu, Kyoto, Japan), which
included a fluorescent detector (Shimadzu RF10XL), C-
10ATvp pumps, SIL-10ADvp auto-injector and STRODS-II
reversed phase column, equipped with post-column deri-
vatisation was set up as previously described [11]. Sam-
ples of the peritoneal cell supernatant/internal standard
solution were injected into the HPLC system using an
autosampler. Histamine and spermidine were detected
with excitation and emission wavelengths of 360 nm and
440 nm, respectively. Four-point standard curves for his-
tamine were prepared, ranging from 50 – 2500 ng/mL in
10 mM HEPES-Tyrode buffer.
Leukotriene B4 production
Synthesis of LTB4 was induced in neutrophils as previ-
ously described [15], with slight modification. Porcine
blood was collected from a local abattoir. Neutrophils
were isolated using a Percoll gradient and suspended in
Hanks' buffer, containing 5 mM HEPES. Suspended neu-
trophils (2.8 × 106 cells/mL) were incubated (37°C) with
RCM-101 extract, NDGA (as a positive control, 0.1, 1 or
10 μg/mL) or vehicle (ethanol), for 5 minutes before the
addition of arachidonic acid (2.5 μM) substrate. Porcine
neutrophils were suspended in Hanks' buffer in concen-
tration of 2.8 × 106 cells/mL. RCM-101 (0.1, 1, 100 μg/
mL) was added 10 minutes before the calcium ionophore
A23187 (2.5 μM). After 5 minute incubation, production
of LTB4 was initiated by the addition of the calcium iono-
phore A23187 (2.5 μM) and 5 minutes later the reaction
was terminated by adjusting the pH to 3 with citric acid.
PGB2 (45 ng) and 15-HETE (83 ng) were then added as
internal standards. The reaction mixture was extracted
with 5 mL of chloroform/methanol (7:3 v/v) and dried
under vacuum. The residue was dissolved in 120 μL of
HPLC mobile phase (methanol-water-acetic acid, 76/34/
0.08, v/v/v, pH 3.0) and leukotriene metabolites were
assayed using a Waters HPLC system equipped with an
auto sampler, a multi-solvent delivery system and a
Waters 996 Photodiode Array Detector. Standard curves
were prepared by the addition of LTB4 (10 – 200 ng) and
5-HETE (500 – 800 ng) to neutrophil suspensions. Data
were analysed using Water Millenium Software, Version
3.2, results being expressed as percentage of the vehicle
control which was taken as 100%.
Prostaglandin E2 production
Murine macrophages (Raw 264.7 cells, American Type
Culture Collection, Rockville, MD, USA) were grown in
RPMI 1640 medium, supplemented with 10% heat-inac-
tivated FBS, 100 μg/mL gentamycin, 1.5 g/L sodium bicar-
bonate and 10 mM HEPES, at 37°C, in an atmosphere
containing 5% CO2. Cells were sub-cultured once a week
by harvesting them with trypsin/EDTA and seeding them
in 75 cm2 flasks. Once confluent, murine macrophages
were suspended in serum-free RPMI medium at concen-
tration of 2 × 105 cells/mL, and the cells were seeded in
24-well plates (1 × 105 cells/well), in serum-free RPMI
medium. Cells were then treated with RCM-101 (1, 10, or
100 μg/mL) or vehicle 10 minutes before the addition of
LPS (1 μg/mL). The supernatant and the cells were sepa-
rated. PGE2  was assayed in the supernatant using an
immune-enzyme analysis kit. The assay depends on com-
petition between PGE2 and PGE2acetylcholinesterase con-
jugate (PGE2-tracer) for a limited amount of monoclonal
PGE2antibody. The assays were carried out according to
the manufacturer's protocol, in triplicate. PGE2 release
was calculated using software supplied by the kit manu-
facturer.
Determination of COX-1 and COX-2 protein expression in 
Raw 264.7 cells
Cultured Raw 264.7 cells prepared as described above for
determination of PGE2  production, with and without
incubation with RCM-101, were washed twice with ice-
cold phosphate buffer saline then lysed with 100 μL/well
of lysis buffer (50 mM Tris base, pH 7.6, 2 mM MgCl2, 1
mM EGTA, 1% TritonX, 1 mM phenyl PMSF, 1 mM pep-
statin, 1 mM aprotinin, 1 mM leupeptin) for 5 minutes.
The cells and the supernatant were collected and centri-
fuged for 5 minutes at 14000 rpm. The cell debris was dis-
carded and the supernatant was assayed for protein
concentration using Coomassie Protein Assay Kit (Bio-
Rad Laboratories Pty Ltd, California, USA) and the UV-vis-
ible spectrophotometer (Cintra 5, GBC Scientific Equip-
ment Pty Ltd, Illinois, USA)
COX-1 and COX-2 protein was measured by Western
blotting as previously described [16] with a slight modifi-
cation. Aliquots of 20 μg of total protein were loaded to
each lane of 7.5% SDS-polyacrylamide gels. The proteins
were then electrically transferred to nitrocellulose mem-
branes which were incubated overnight with a polyclonal
anti-rabbit COX-1 antibody or a monoclonal mouse anti-
rat COX-2 antibody (diluted 1:500 and 1:2500 respec-
tively) in 5% non-fat milk in Tris-buffered saline (Tris
base 25 mM, glycine 19 mM, methanol 20%). On the next
day, membranes were washed with Tris-buffered saline
(Tris base 20 mM, NaCl 137 mM, Tween-20 0.1%, pH
7.5) for 40 minutes with constant agitation, during which
time the buffer was changed every 5 minutes. The mem-Chinese Medicine 2007, 2:2 http://www.cmjournal.org/content/2/1/2
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branes were then incubated with swine anti-rabbit or goat
anti-mouse secondary conjugated to horseradish peroxi-
dase diluted 1:5000 with blocking buffer (Tris base 20
mM, NaCl 137 mM, Tween-20 0.1%, pH 7.5 and 5% non-
fat milk). The results were visualized by enhanced chemi-
luminescence (Amersham Pharmacia Biotech) according
to the manufacturer's instructions.
Statistical analysis
Data are expressed as means ± standard deviation (SD).
The statistical significance of differences between means
was determined by unpaired, two-tailed Student's t-test
or, for more than two groups, by first testing for global dif-
ferences by one- or two-way analysis of variance (ANOVA)
and then testing for differences between predetermined
pairs of means by Dunnet's test. The differences with
probability levels less than 0.05 (P < 0.05) were consid-
ered to be statistically significant.
Results
Inhibition of compound 48/80-induced histamine release 
from rat peritoneal mast cells
The amount of histamine released from rat unstimulated
peritoneal mast cell preparations was 46.3 ± 37.1 ng/mL
(n = 14). When the cells were stimulated with compound
48/80 (1 μg/mL) histamine release increased markedly to
638.3 ± 308 ng/mL (n = 14). As shown in Figure 1, com-
pound 48/80-induced histamine release was inhibited by
RCM-101 (1 – 100 μg/mL) in a concentration dependent
manner. Compound 48/80-induced histamine release
was also reduced by 10μM EDTA (Figure 1).
Inhibition of leukotriene B4 production in porcine 
neutrophils
In the absence of calcium ionophore A23187 incubation,
the production of LTB4 by porcine neutrophils was 9.58 ±
4.6 ng/mL. In vehicle (ethanol) control experiments,
A23187 incubation increased LTB4 production to 167.77
± 70.4 ng/mL (n = 8).
As shown in Figure 2, LTB4 production in A23187-incu-
bated neutrophils was inhibited by RCM-101 at concen-
trations of 1 and 10 μg/mL. NDGA (1 and 10 μg/mL) also
inhibited A23187-induced LTB4 production.
Inhibition of prostaglandin E2 production in LPS-
stimulated Raw 264.7 cells
Unstimulated Raw 267.4 cells incubated in serum-free
RPMI medium for 24 hours produced a baseline concen-
tration of PGE2 of 52 ± 24.4 pg/mL (n = 6). Incubating the
cells with LPS (1 μg/mL) increased the PGE2 level to 3874
± 818.13 pg/mL (n = 6). This induced production of PGE2
was reduced in a concentration-dependent manner by
RCM-101 (1 – 100 μg/mL), when present during incuba-
tion with LPS. Indomethacin (1, 10 and 100 μM), when
Inhibition of LTB4 formation in porcine neutrophils by RCM- 101 and nordihydroguaiaretic acid (NDGA) Figure 2
Inhibition of LTB4 formation in porcine neutrophils by RCM-
101 and nordihydroguaiaretic acid (NDGA). Data are plotted 
as means ± SD, (n = 8 in each case). *P < 0.05, One-way 
ANOVA and Dunnet's test
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Inhibition of compound 48/80-stimulated histamine release  from rat peritoneal mast cells by RCM-101 Figure 1
Inhibition of compound 48/80-stimulated histamine release 
from rat peritoneal mast cells by RCM-101. EDTA was used 
as a positive control. Data are plotted as means ± SD, (n = 
8). *P < 0.05, One-way ANOVA and Dunnet's test
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present during LPS incubation, completely blocked PGE2
production. The data are shown in Figure 3.
Effects of RCM-101 on COX-1 and COX-2 protein 
expression in LPS-stimulated Raw 267.4 cells
As shown in Figure 4, immunoreactivity bands corre-
sponding to COX-1 and COX-2 (70 kDa) were detected by
Western blot analysis of the supernatant of lysed Raw
264.7 cells. Densiometeric analysis of the marker chemi-
luminescence indicated that expression of COX-1 protein
was unaffected by RCM-101 (10 and 100 μg/mL). Simi-
larly, dexamethasone (10 and 100 μM) also did not alter
COX-1 protein expression. In contrast, the expression of
COX-2 protein was significantly (P < 0.05, one-way
ANOVA, Dunnet's test) reduced by 100 μg/mL RCM-101
and also by 100 μM dexamethasone. Figure 4 shows
examples of the visualised bands on nitrocellulose mem-
branes corresponding to COX-1 and COX-2 proteins.
Discussion
This study was undertaken to extend our previous investi-
gation of possible pharmacological mechanisms for the
effects of the herbal formula RCM-101 in reducing SAR
symptoms [10]. The main findings of the present study
are that RCM-101 inhibits compound 48/80-induced
release of histamine from isolated rat peritoneal mast cells
and inhibits the production of LTB4  by porcine neu-
trophils and of PGE2 by Raw 264.7 cells. Histamine, PGE2
and LTB4 are well known mediators of inflammatory/
allergic responses. Taken together with our previous find-
ings in isolated tissues from rats and guinea-pigs, it seems
that RCM-101, a herbal formula with 18 constituent Chi-
nese herbs, has activity directed to inhibition of the syn-
thesis or release of multiple key inflammatory mediators.
Mast cell-derived mediators, particularly histamine are
considered to be responsible for the acute (early stage)
allergic symptoms of SAR [17]. These mediators act on the
smooth muscle cells of small blood vessels, blood plate-
lets, mucous glands and sensory nerve endings to produce
or contribute to symptoms such as nasal congestion, nasal
and throat itching, sneezing and hypersecretion of mucus
[18]. The release of mast cell-derived histamine is inhib-
ited by RCM-101. While the inhibition mechanisms are
not clear, RCM-101 has been shown to contain several
herbal ingredients that inhibit the release or action of his-
tamine. For example, Rhizoma Cimicifugae was reported to
exert a potent inhibitory action on histamine-mediated
contractions in guinea pig ileum [19] and Flos Magnoliae
inhibits mast cell-mediated allergic reactions by prevent-
ing mast cell degranulation and IgE-mediated histamine
release [20]. Herba Schizonepetae was also reported to
reduce compound 48/80-induced histamine release [21].
Moreover, the Chinese herbal formula Xiao Chai Hu Tang,
which contains several of the herbal ingredients of RCM-
101, has also been shown to inhibit histamine release
from rat peritoneal mast cells [11].
Limited information is available about the chemical con-
stituents of the herbs in RCM-101 responsible for inhibi-
tion of the release or action of histamine or their action
mechanisms. However, glycyrrhetinic acid, which is
Western blot assay of COX-1 and COX-2 expression by  macrophage (Raw 264.7. 20) cells after LPS stimulation Figure 4
Western blot assay of COX-1 and COX-2 expression by 
macrophage (Raw 264.7. 20) cells after LPS stimulation. For 
each lane of SDS polyacrylamide gels, 20 μg of protein was 
loaded. COX-1 and COX-2. The proteins were detected on 
nitrocellulose membranes using specific antibodies and visual-
ized by enhanced chemiluminescence. (A) COX-1: VC = 
vehicle control; S = separation lane (not loaded with pro-
tein); D1 = dexamethasone (100 μM); D2 = dexamethasone 
(10 μM); R1 = RCM-101 (100 μg/mL); R2 = RCM-101 (10 μg/
mL); PC = positive control (COX-1 lysate). (B) COX-2: VC 
= vehicle control; B = cells not stimulated with LPS; R = 
RCM-101 (100 μg/mL); D = dexamethasone (100 μM); PC = 
positive control (COX-2 lysate).
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Inhibition of PGE2 production in LPS-stimulated Raw 264 Figure 3
Inhibition of PGE2 production in LPS-stimulated Raw 264.7 
cells by RCM-101 and indomethacin. Data are plotted as 
means ± SD of percentage control PGE2 production (n = 6 in 
each case). *P < 0.05, One-way ANOVA and Dunnet's test
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present in Radix Glycyrrhizae, a herbal component of
RCM-101, was shown to inhibit the release of histamine
by targeting protein kinase C-β (nPKC β) [22]. Conju-
gated linoleic acid, identified in Rhizoma Chuanxiong,
another herbal component of the formula, is known to
inhibit immediate anaphylaxis, histamine release and the
synthesis of arachidonic acid metabolites [23].
Prostaglandins and leukotrienes were found to be
involved in the pathophysiology of SAR [24] and LTB4 is
released by infiltrating neutrophils during the immediate
phase of allergic responses [25]. The present study found
that RCM-101 inhibits the production/release of LTB4
induced by the calcium ionophore A23187 in porcine
neutrophils. Previous studies showed that extracts of the
herb Radix Glycyrrhizae inhibit A23187-induced release of
arachidonic acid from cell membranes by inhibiting
phospolipaseA2 and that they also inhibit 5-lipoxygenase,
acting together to suppress the production of LTC4 and
LTB4 [26]. Glycyrrhetinic acid and caffeic acid, present in
Radix Glycyrrhizae,  Herba Menthae,  Rhizoma Ligusticum
Chuanxiong  and  Rhizoma Cimicifugae [27], both were
shown to inhibit arachidonic metabolite formation
[28,29]. These findings suggest a possible action of RCM-
101 on SAR through the inhibition of the release of LTB4.
PGE2 is released in both the early phase (from mast cells)
and late phase (from basophils and eosinophils)
responses of SAR [17]. We found that LPS-induced pro-
duction of PGE2 by murine macrophages was inhibited by
RCM-101. The findings are consistent with previous stud-
ies on individual herbal components of RCM-101. There
is also evidence indicating that Radix Glycyrrhizae inhibits
PGE2 production in rats tissues and Rhizoma Cimicifugae
blocks LPS-induced production of PGE2 [19]. In addition,
both topical and oral administration glycyrrhetinic acid
was reported to prevent ear oedema and to inhibit PGE2
and LTC4 formation induced by arachidonic acid in mice
[30]. These findings suggest a possible action of RCM-101
on SAR through the inhibition of PGE2 production.
The inhibition of prostaglandin production by RCM-101
is most likely due to inhibition of COX-2 protein expres-
sion, because we observed that COX-2 protein expression
was markedly reduced by RCM-101 whereas the expres-
sion of COX-1 protein was unaffected. It is known that
COX-2 is responsible for prostaglandin production in
Raw 264.7 cells [14]. Previous studies also observed that
Rhizoma Cimicifugae and  Radix Glycyrrhizae inhibited
COX-2 activity [26].
Conclusion
The results obtained in this study indicate that RCM-101
has inhibitory actions on multiple inflammatory media-
tors, including the release of histamine from mast cells,
and production of LTB4 and PGE2 by neutrophils and Raw
264.7 cells, respectively. In addition, RCM-101 also selec-
tively inhibits the expression of the inducible enzyme
COX-2. These actions of RCM-101 may contribute to its
efficacy in SAR. The exact mechanisms of these actions
and the contributions by individual herbal ingredients of
RCM-101 require further investigation.
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